Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer
J. Clin. Invest. Raffaele Ciampi, et al. 115:94 doi:10.1172/JCI23237 [Go to this article.]

Figure 3
Subcellular localization of AKAP9 and AKAP9-BRAF detected by immunohistochemistry with an AKAP9 antibody. (A) In a papillary thyroid carcinoma negative for the fusion, the protein is predominantly targeted to centrosomes, seen as a single perinuclear dot. There is also weak diffuse cytoplasmic staining. (B) The tumor expressing AKAP9-BRAF reveals diffuse cytoplasmic distribution of the chimeric protein and the perinuclear dot is no longer visible. The shift in localization involves only tumor cells but not adjacent vascular endothelial cells, which preserve the dotted pattern of staining (arrow). Magnification, ×200.